The TGA has signed off on a change to prescribing information for dabigatran (Pradaxa) confirming it as the only NOAC that can be continued in patients with atrial fibrillation undergoing a catheter ablation for rhythm control. The change is consistent with the recently published NHFA/CSANZ Australia Clinical Guidelines for the Diagnosis and Management of Atrial ...
First NOAC approved for uninterrupted use in AF ablation
By Mardi Chapman
12 Sep 2018